Takeda Pharmaceutical (4502) Stock Overview
Engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 5/6 |
4502 Community Fair Values
Create NarrativeSee what 18 others think this stock is worth. Follow their fair value or set your own to get alerts.
Takeda Pharmaceutical Company Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥4,493.00 |
| 52 Week High | JP¥4,670.00 |
| 52 Week Low | JP¥3,916.00 |
| Beta | 0.27 |
| 1 Month Change | 2.91% |
| 3 Month Change | 3.31% |
| 1 Year Change | 8.61% |
| 3 Year Change | 15.74% |
| 5 Year Change | 12.63% |
| Change since IPO | 232.81% |
Recent News & Updates
Recent updates
Takeda Pharmaceutical (TSE:4502) Is Increasing Its Dividend To ¥100.00
Sep 03
Takeda Pharmaceutical's (TSE:4502) Soft Earnings Are Actually Better Than They Appear
Aug 08Takeda Pharmaceutical's (TSE:4502) Upcoming Dividend Will Be Larger Than Last Year's
Aug 07Takeda Pharmaceutical Company Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Aug 02Takeda Pharmaceutical (TSE:4502) Is Increasing Its Dividend To ¥100.00
Jul 24Takeda Pharmaceutical (TSE:4502) Will Pay A Larger Dividend Than Last Year At ¥100.00
Jul 10Takeda Pharmaceutical Company Limited Just Missed Earnings - But Analysts Have Updated Their Models
Jun 28Takeda Pharmaceutical Company Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
May 11These 4 Measures Indicate That Takeda Pharmaceutical (TSE:4502) Is Using Debt Reasonably Well
May 07Takeda Pharmaceutical's (TSE:4502) Dividend Will Be ¥98.00
Mar 18Takeda Pharmaceutical (TSE:4502) Will Pay A Dividend Of ¥98.00
Mar 03Earnings Tell The Story For Takeda Pharmaceutical Company Limited (TSE:4502)
Feb 27The Strong Earnings Posted By Takeda Pharmaceutical (TSE:4502) Are A Good Indication Of The Strength Of The Business
Feb 06Takeda Pharmaceutical Company Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Feb 04Takeda Pharmaceutical's (TSE:4502) Dividend Will Be ¥98.00
Jan 30Takeda Pharmaceutical (TSE:4502) Is Due To Pay A Dividend Of ¥98.00
Dec 31Takeda Pharmaceutical's (TSE:4502) Dividend Will Be ¥98.00
Dec 17Takeda Pharmaceutical's (TSE:4502) Dividend Will Be ¥98.00
Dec 03Here's Why Takeda Pharmaceutical (TSE:4502) Can Manage Its Debt Responsibly
Nov 25
Tactical Innovation And Global Expansion To Propel Growth Amid Market Challenges
Anticipated efficiency gains and strategic expansions are expected to boost profit margins and revenue through new product launches and market share growth.Results: Takeda Pharmaceutical Company Limited Exceeded Expectations And The Consensus Has Updated Its Estimates
Nov 04Takeda Pharmaceutical (TSE:4502) Is Increasing Its Dividend To ¥98.00
Sep 24Why Investors Shouldn't Be Surprised By Takeda Pharmaceutical Company Limited's (TSE:4502) P/E
Sep 20Shareholder Returns
| 4502 | JP Pharmaceuticals | JP Market | |
|---|---|---|---|
| 7D | -1.8% | -0.4% | 1.8% |
| 1Y | 8.6% | -4.5% | 22.1% |
Return vs Industry: 4502 exceeded the JP Pharmaceuticals industry which returned -4.5% over the past year.
Return vs Market: 4502 underperformed the JP Market which returned 22.1% over the past year.
Price Volatility
| 4502 volatility | |
|---|---|
| 4502 Average Weekly Movement | 2.5% |
| Pharmaceuticals Industry Average Movement | 3.4% |
| Market Average Movement | 3.3% |
| 10% most volatile stocks in JP Market | 7.5% |
| 10% least volatile stocks in JP Market | 1.7% |
Stable Share Price: 4502 has not had significant price volatility in the past 3 months compared to the JP market.
Volatility Over Time: 4502's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1781 | 47,455 | Christophe Weber | www.takeda.com |
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands.
Takeda Pharmaceutical Company Limited Fundamentals Summary
| 4502 fundamental statistics | |
|---|---|
| Market cap | JP¥7.02t |
| Earnings (TTM) | JP¥136.92b |
| Revenue (TTM) | JP¥4.48t |
Is 4502 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4502 income statement (TTM) | |
|---|---|
| Revenue | JP¥4.48t |
| Cost of Revenue | JP¥1.57t |
| Gross Profit | JP¥2.91t |
| Other Expenses | JP¥2.77t |
| Earnings | JP¥136.92b |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Oct 30, 2025
| Earnings per share (EPS) | 87.66 |
| Gross Margin | 64.98% |
| Net Profit Margin | 3.06% |
| Debt/Equity Ratio | 65.6% |
How did 4502 perform over the long term?
See historical performance and comparisonDividends
Does 4502 pay a reliable dividends?
See 4502 dividend history and benchmarks| Takeda Pharmaceutical dividend dates | |
|---|---|
| Ex Dividend Date | Sep 29 2025 |
| Dividend Pay Date | Dec 02 2025 |
| Days until Ex dividend | 14 days |
| Days until Dividend pay date | 78 days |
Does 4502 pay a reliable dividends?
See 4502 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/09/13 19:48 |
| End of Day Share Price | 2025/09/12 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Takeda Pharmaceutical Company Limited is covered by 36 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Atsushi Seki | Barclays |
| Koichi Mamegano | BofA Global Research |
| Hazim Bahari | CFRA Equity Research |